TVARDI THERAPEUTICS, INC. Impairment of Long-Lived Assets Held-for-use
TVARDI THERAPEUTICS, INC. (TVRD) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-31
- TVARDI THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2024-12-31 was -$4.27M.
- TVARDI THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $4.27M.
- TVARDI THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00.
- TVARDI THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00.
- TVARDI THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- TVARDI THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 | ||||
| 2024-12-31 | -$4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 | $4.27M 10-K · filed 2025-03-11 | |
| 2024-09-30 | $4.27M 10-Q · filed 2024-11-14 | $4.27M 10-Q · filed 2024-11-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |